amivantamab-vmjw
FDA Approves Rybrevant for NSCLC With EGFR Exon 19 Deletions or L858R Mutations
The FDA has approved Rybrevant with carboplatin and pemetrexed for adult patients with locally advanced or ...
SEPTEMBER 23, 2024
FDA Approves Rybrevant for EGFR Exon 20 Insertion-Mutated NSCLC Indications
The FDA approved Rybrevant with carboplatin and pemetrexed for the first-line treatment of locally advanced or ...
MARCH 5, 2024
FDA Approves Rybrevant for Advanced NSCLC With EGFR Mutations
The FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech) for the treatment of adults ...
MAY 25, 2021
Load more